Why the investor craze for Ozempic and rival weight-loss drugs may resume next year 0 16.12.2024 18:18 MarketWatch.com Novo Nordisk’s takeover of Catalent and the Danish firm’s push to launch a new generation of drugs could boost the importance of GLP agonists in 2025, Barclays analysts said Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
